Clofibrate-induced changes in the liver, heart, brain and white adipose lipid metabolome of Swiss-Webster mice

Craig E. Wheelock, Susumu Goto, Bruce D. Hammock, John W. Newman

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Peroxisome proliferator activated receptor alpha (PPARα) agonists are anti-hyperlipidemic drugs that influence fatty acid combustion, phospholipid biosynthesis and lipoprotein metabolism. To evaluate impacts on other aspects of lipid metabolism, we applied targeted metabolomics to liver, heart, brain and white adipose tissue samples from male Swiss-Webster mice exposed to a 5day, 500 mg/kg/day regimen of i.p. clofibrate. Tissue concentrations of free fatty acids and the fatty acid content of sphingomyelin, cardiolipin, cholesterol esters, triglycerides and phospholipids were quantified. Responses were tissue-specific, with changes observed in the liver > heart > > brain > adipose. These results indicate that liver saturated fatty acid-rich triglycerides feeds clofibrate-induced monounsaturated fatty acid (MUFA) synthesis, which were incorporated into hepatic phospholipids and sphingomyelin. In addition, selective enrichment of docosahexeneoic acid in the phosphatidylserine of liver (1.7-fold), heart (1.6-fold) and brain (1.5-fold) suggests a clofibrate-dependent systemic activation of phosphatidylserine synthetase 2. Furthermore, the observed ∼20% decline in cardiac sphingomyelin is consistent with activation of a sphingomeylinase with a substrate preference for polyunsaturate-containing sphingomyelin. Finally, perturbations in the liver, brain, and adipose cholesterol esters were observed, with clofibrate exposure elevating brain cholesterol arachidonyl-esters ∼20-fold. Thus, while supporting previous findings, this study has identified novel impacts of PPARα agonist exposure on lipid metabolism that should be further explored.

Original languageEnglish (US)
Pages (from-to)137-145
Number of pages9
JournalMetabolomics
Volume3
Issue number2
DOIs
StatePublished - Jun 2007

Fingerprint

Clofibrate
Metabolome
Liver
Sphingomyelins
Brain
Lipids
Cholesterol Esters
PPAR alpha
Phospholipids
Fatty Acids
Tissue
CDPdiacylglycerol-Serine O-Phosphatidyltransferase
Lipid Metabolism
Triglycerides
Chemical activation
Monounsaturated Fatty Acids
Cardiolipins
Phosphatidylserines
Biosynthesis
White Adipose Tissue

Keywords

  • Clofibrate
  • Extra-hepatic
  • Lipid metabolism
  • Metabolomics
  • PPAR-alphaagonist
  • Sphingomyelin

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Clofibrate-induced changes in the liver, heart, brain and white adipose lipid metabolome of Swiss-Webster mice. / Wheelock, Craig E.; Goto, Susumu; Hammock, Bruce D.; Newman, John W.

In: Metabolomics, Vol. 3, No. 2, 06.2007, p. 137-145.

Research output: Contribution to journalArticle

Wheelock, Craig E. ; Goto, Susumu ; Hammock, Bruce D. ; Newman, John W. / Clofibrate-induced changes in the liver, heart, brain and white adipose lipid metabolome of Swiss-Webster mice. In: Metabolomics. 2007 ; Vol. 3, No. 2. pp. 137-145.
@article{0350c537d0154e0bbca3d844672e617c,
title = "Clofibrate-induced changes in the liver, heart, brain and white adipose lipid metabolome of Swiss-Webster mice",
abstract = "Peroxisome proliferator activated receptor alpha (PPARα) agonists are anti-hyperlipidemic drugs that influence fatty acid combustion, phospholipid biosynthesis and lipoprotein metabolism. To evaluate impacts on other aspects of lipid metabolism, we applied targeted metabolomics to liver, heart, brain and white adipose tissue samples from male Swiss-Webster mice exposed to a 5day, 500 mg/kg/day regimen of i.p. clofibrate. Tissue concentrations of free fatty acids and the fatty acid content of sphingomyelin, cardiolipin, cholesterol esters, triglycerides and phospholipids were quantified. Responses were tissue-specific, with changes observed in the liver > heart > > brain > adipose. These results indicate that liver saturated fatty acid-rich triglycerides feeds clofibrate-induced monounsaturated fatty acid (MUFA) synthesis, which were incorporated into hepatic phospholipids and sphingomyelin. In addition, selective enrichment of docosahexeneoic acid in the phosphatidylserine of liver (1.7-fold), heart (1.6-fold) and brain (1.5-fold) suggests a clofibrate-dependent systemic activation of phosphatidylserine synthetase 2. Furthermore, the observed ∼20{\%} decline in cardiac sphingomyelin is consistent with activation of a sphingomeylinase with a substrate preference for polyunsaturate-containing sphingomyelin. Finally, perturbations in the liver, brain, and adipose cholesterol esters were observed, with clofibrate exposure elevating brain cholesterol arachidonyl-esters ∼20-fold. Thus, while supporting previous findings, this study has identified novel impacts of PPARα agonist exposure on lipid metabolism that should be further explored.",
keywords = "Clofibrate, Extra-hepatic, Lipid metabolism, Metabolomics, PPAR-alphaagonist, Sphingomyelin",
author = "Wheelock, {Craig E.} and Susumu Goto and Hammock, {Bruce D.} and Newman, {John W.}",
year = "2007",
month = "6",
doi = "10.1007/s11306-007-0052-8",
language = "English (US)",
volume = "3",
pages = "137--145",
journal = "Metabolomics",
issn = "1573-3882",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Clofibrate-induced changes in the liver, heart, brain and white adipose lipid metabolome of Swiss-Webster mice

AU - Wheelock, Craig E.

AU - Goto, Susumu

AU - Hammock, Bruce D.

AU - Newman, John W.

PY - 2007/6

Y1 - 2007/6

N2 - Peroxisome proliferator activated receptor alpha (PPARα) agonists are anti-hyperlipidemic drugs that influence fatty acid combustion, phospholipid biosynthesis and lipoprotein metabolism. To evaluate impacts on other aspects of lipid metabolism, we applied targeted metabolomics to liver, heart, brain and white adipose tissue samples from male Swiss-Webster mice exposed to a 5day, 500 mg/kg/day regimen of i.p. clofibrate. Tissue concentrations of free fatty acids and the fatty acid content of sphingomyelin, cardiolipin, cholesterol esters, triglycerides and phospholipids were quantified. Responses were tissue-specific, with changes observed in the liver > heart > > brain > adipose. These results indicate that liver saturated fatty acid-rich triglycerides feeds clofibrate-induced monounsaturated fatty acid (MUFA) synthesis, which were incorporated into hepatic phospholipids and sphingomyelin. In addition, selective enrichment of docosahexeneoic acid in the phosphatidylserine of liver (1.7-fold), heart (1.6-fold) and brain (1.5-fold) suggests a clofibrate-dependent systemic activation of phosphatidylserine synthetase 2. Furthermore, the observed ∼20% decline in cardiac sphingomyelin is consistent with activation of a sphingomeylinase with a substrate preference for polyunsaturate-containing sphingomyelin. Finally, perturbations in the liver, brain, and adipose cholesterol esters were observed, with clofibrate exposure elevating brain cholesterol arachidonyl-esters ∼20-fold. Thus, while supporting previous findings, this study has identified novel impacts of PPARα agonist exposure on lipid metabolism that should be further explored.

AB - Peroxisome proliferator activated receptor alpha (PPARα) agonists are anti-hyperlipidemic drugs that influence fatty acid combustion, phospholipid biosynthesis and lipoprotein metabolism. To evaluate impacts on other aspects of lipid metabolism, we applied targeted metabolomics to liver, heart, brain and white adipose tissue samples from male Swiss-Webster mice exposed to a 5day, 500 mg/kg/day regimen of i.p. clofibrate. Tissue concentrations of free fatty acids and the fatty acid content of sphingomyelin, cardiolipin, cholesterol esters, triglycerides and phospholipids were quantified. Responses were tissue-specific, with changes observed in the liver > heart > > brain > adipose. These results indicate that liver saturated fatty acid-rich triglycerides feeds clofibrate-induced monounsaturated fatty acid (MUFA) synthesis, which were incorporated into hepatic phospholipids and sphingomyelin. In addition, selective enrichment of docosahexeneoic acid in the phosphatidylserine of liver (1.7-fold), heart (1.6-fold) and brain (1.5-fold) suggests a clofibrate-dependent systemic activation of phosphatidylserine synthetase 2. Furthermore, the observed ∼20% decline in cardiac sphingomyelin is consistent with activation of a sphingomeylinase with a substrate preference for polyunsaturate-containing sphingomyelin. Finally, perturbations in the liver, brain, and adipose cholesterol esters were observed, with clofibrate exposure elevating brain cholesterol arachidonyl-esters ∼20-fold. Thus, while supporting previous findings, this study has identified novel impacts of PPARα agonist exposure on lipid metabolism that should be further explored.

KW - Clofibrate

KW - Extra-hepatic

KW - Lipid metabolism

KW - Metabolomics

KW - PPAR-alphaagonist

KW - Sphingomyelin

UR - http://www.scopus.com/inward/record.url?scp=34249870602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249870602&partnerID=8YFLogxK

U2 - 10.1007/s11306-007-0052-8

DO - 10.1007/s11306-007-0052-8

M3 - Article

VL - 3

SP - 137

EP - 145

JO - Metabolomics

JF - Metabolomics

SN - 1573-3882

IS - 2

ER -